Many AAOS exhibitors are addressing needs "beyond the device": systems to manage patient care, to deliver the implant to the clinic or get it into the body in a more efficient manner or make it work better once it's in. We've highlighted a few exhibitors to help you--and us--get to know them better.
Early last year, we published results of an ORTHOWORLD Membership survey in ORTHOKNOW. Among the questions, we asked you to predict: In 2017, where do the opportunities lie for you and your company? Let's look back at what happened.
Each year, ORTHOWORLD publishes THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®. This year, we endeavor to collect your voice beforehand in an 8-question survey that takes just 3 minutes to complete. We will use survey answers and data in the 2018 report, where helpful.
Companies throughout the supply chain stand to benefit from the U.S.'s lowered Federal corporate tax, setting up industry stakeholders to invest in themselves in 2018. We expect that companies will use kept earnings to support R&D, job creation and potentially, mergers and acquisitions.
The WHITE Four randomized control trial, comparing the X-Bolt expanding bolt device to a sliding hip screw, has surpassed enrollment of 1,000 patients.
PALACOS has been sold and supported via direct sales in Australia, Europe and other countries through an integrated ordering process that is now available to U.S. customers.
Cellesta, a full line of placental allograft products for surgical and non-surgical applications, will be available in the U.S. in flowable and sheet formats.
Tendonoid Web Joint technology creates an implant that "floats" the patient's weight on a web of UHMWPE cords, allowing anatomical range of motion without wear debris generation.
Specifically, over 14 months, 1,380 TJAs were conducted under the program with partner Provider PPI, with only two readmissions--a rate of 0.145%, vs. rates of 5.3% or more published in 2013.
